Simeon George
CIK 1595117 · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$163.82M
Companies
11
Total Filings
48
Lifetime Open-Market Net
$406.11M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NKTX | Director | 666,667 | $2.12 | $1.41M | $40.00M | 9 | 2026-06-11 |
| DSGN | Director | 6,486,476 | $11.94 | $77.45M | $12.57M | 8 | 2026-06-11 |
| CRSP | Director | 238,897 | $47.55 | $11.36M | $51.50M | 11 | 2026-06-09 |
| ODTX | 10%+ Owner | 734,868 | $18.02 | $13.24M | $19.94M | 1 | 2026-05-11 |
| AVLN | 10%+ Owner | 1,419,298 | $27.92 | $39.63M | $20.00M | 1 | 2026-05-01 |
| ZBIO | 10%+ Owner | 669,061 | $31.00 | $20.74M | $76.00M | 1 | 2024-09-16 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 0 | $76.01 | $0 | $18.85M | 6 | 2022-08-17 |
| Arcellx, Inc. (ACLX) Delisted | 10%+ Owner | 2,216,960 | $115.07 | $255.11M | $150.00M | 1 | 2022-02-10 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | 0 | — | — | $14.59M | 6 | 2020-09-28 |
| CRISPR Therapeutics AG (PZRX) Delisted | Director | 3,220,627 | — | — | $931.0K | 3 | 2017-06-02 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Director | 114,933 | $0.00 | $69 | $1.73M | 1 | 2014-02-11 |
Recent Filings · Page 5 of 5
48 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-04-24 | Turning Point Therapeutics, Inc. (TPTX) Delisted | Mixed | +1,992,550 | $5.85M | EDGAR |
| 2019-01-10 | Principia Biopharma Inc. (PRNB) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-09-20 | Principia Biopharma Inc. (PRNB) Delisted | Mixed | +2,625,713 | $4.59M | EDGAR |
| 2018-06-19 | CRSP | Grant (A) | — | $0 | EDGAR |
| 2017-06-02 | CRISPR Therapeutics AG (PZRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-10-26 | CRISPR Therapeutics AG (PZRX) Delisted | Mixed | +3,220,627 | $931.0K | EDGAR |
| 2016-10-20 | CRISPR Therapeutics AG (PZRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-02-11 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Mixed | +1,671,667 | $1.73M | EDGAR |
Showing 41–48 of 48
Prev
Page 5 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.